MCAM and prostate adenocarcinoma: Our studies also indicate that over-expression of METCAM/MUC18 augments tumorigenesis of prostate adenocarcinoma [31], breast carcinoma [28,29] and nasopharyngeal carcinoma type II [32,33] but it does not have an effect on tumorigenesis of melanoma [26,34].